Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark B Abelson

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Clinical Therapeutics|August 17, 2002
Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challengeBob Q Lanier, Mark B Abelson, William E Berger, et al.
American Journal of Ophthalmology|December 4, 2003
Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitisJack V Greiner, Thomas Mundorf, Harvey Dubiner, et al.
Allergy and Asthma Proceedings|April 2, 2004
Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administrationCullen T Vogelson, Mark B Abelson, Terri Pasquine, et al.
Clinical Ophthalmology (Auckland, N.Z.)|August 14, 2018
Cone photoreceptor macular function and recovery after photostress in early non-exudative age-related macular degenerationJohn D Rodriguez, Keith Lane, David A Hollander, et al.
Clinical Ophthalmology (Auckland, N.Z.)|March 18, 2025
Statistical Evaluation of Smartphone-Based Automated Grading System for Ocular Redness Associated with Dry Eye Disease and Implications for Clinical TrialsJohn D Rodriguez, Adam Hamm, Ethan Bensinger, et al.
Clinical Therapeutics|October 13, 2004
Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental studyMark B Abelson, Paul J Gomes, Cullen T Vogelson, et al.
The Journal of Allergy and Clinical Immunology|October 5, 2016
Validation of the Global Allergy and Asthma European Network (GA<sup>2</sup>LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamberTorsten Zuberbier, Mark B Abelson, Cezmi A Akdis, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Clinical Therapeutics|August 17, 2002
Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challengeBob Q Lanier, Mark B Abelson, William E Berger, et al.
American Journal of Ophthalmology|December 4, 2003
Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitisJack V Greiner, Thomas Mundorf, Harvey Dubiner, et al.
Allergy and Asthma Proceedings|April 2, 2004
Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administrationCullen T Vogelson, Mark B Abelson, Terri Pasquine, et al.
Clinical Ophthalmology (Auckland, N.Z.)|August 14, 2018
Cone photoreceptor macular function and recovery after photostress in early non-exudative age-related macular degenerationJohn D Rodriguez, Keith Lane, David A Hollander, et al.
Clinical Ophthalmology (Auckland, N.Z.)|March 18, 2025
Statistical Evaluation of Smartphone-Based Automated Grading System for Ocular Redness Associated with Dry Eye Disease and Implications for Clinical TrialsJohn D Rodriguez, Adam Hamm, Ethan Bensinger, et al.
Clinical Therapeutics|October 13, 2004
Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental studyMark B Abelson, Paul J Gomes, Cullen T Vogelson, et al.
The Journal of Allergy and Clinical Immunology|October 5, 2016
Validation of the Global Allergy and Asthma European Network (GA<sup>2</sup>LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamberTorsten Zuberbier, Mark B Abelson, Cezmi A Akdis, et al.
Pageof 7